Skip to content

Reimbursement Information

Reimbursement information on coding, coverage and payment amounts for Ultromics EchoGo® Heart Failure

Our Partnership Goals are to: 



  • Help achieve faster and more precise heart failure diagnoses that will improve patient outcomes 
  • Widen our existing knowledge base and increase our expertise on heart failure
  • Continue to speed up AI innovation and scale up our platforms

 



  • Maintain our close connections within the global scientific community
  • Increase inter-industry and academic-industry collaborations

What We Have Achieved with our Partnerships

Published Research and Validation

Through our partnerships with Mayo Clinic, Janssen, and the NHS, we have trained and tested our technology to ensure trust for providers. This technology has gone on to be peer-reviewed in JACC and JASE. 

Reliability in the heart failure sector

With our partners’ continuous support, our technology has proven its reliability through commercial clearances, including three FDA clearances, two CE marks, and two FDA breakthrough designations. 

Access to world-leading science and data

Our technology was built on ten years of outcome data. We were born out of Oxford University from leading minds in science and built in partnership with the U.K.’s National Health Service (NHS).  

We are committed to ongoing partnerships with leading organizations as we seek to achieve continuous improvement of our unparalleled AI technology. 

Building a community of medical and tech experts

We have brought together some of the world’s top experts in both medical science and AI technology to maximize the application of our groundbreaking platform. We’ve built a world-leading Scientific Advisory Board with key industry experts from Northwestern Medicine, Baylor Scott & White, Mayo Clinic, and Harvard Medical Center.

Heart Failure Looking for Partnerships?   We'd like to hear from you and your interest in improving the diagnosis and treatment of heart failure.   

 

What others say about our partnerships:



After Ultromics joined as a full partner The Accelerating Medicines Partnership® Heart Failure (AMP® HF), which includes the National Heart Lung and Blood Institute (NHLBI): 

Reimbursement Resources

EchoGo® is a revolutionary AI-powered platform designed to assist healthcare professionals in the diagnosis and management of cardiac diseases. The technology utilizes advanced artificial intelligence to detect disease non-invasively using echocardiography, providing diagnostic outputs to support in the timely detection and effective management of diseases.

EchoGo® Heart Failure

EchoGo® Heart Failure is eligible for reimbursement in both
outpatient and inpatient settings.

Below you will find the necessary coding information and payment methodologies for
ensuring proper reimbursement. 

Hospital OutPatient

In hospital outpatient settings, the technical component of EchoGo®  Heart Failure is billed using HCPCS code C9786. This is paid through the Ambulatory Payment Classification (APC) system under APC 5743, with a national average payment of $284.88 (adjusted by the wage index for each hospital provider). 

Note: As of January 1, 2025 the HCPCS code will sunset and outpatient technical component reimbursement will be paid by Category III CPT code with a national average payment of $297.99 (adjusted by the wage index for each hospital provider)

Hospital InPatient

For inpatient settings, EchoGo® Heart Failure may qualify for the New Technology Add-on Payment (NTAP) if the total cost of care exceeds the MS-DRG payment. Medicare will reimburse $0.65 for every dollar of excess cost, up to a maximum of $1,023.75.

Questions?

Ultromics is working closely with providers to establish coverage with commercial players.
For specific reimbursement
questions, please contact us directly. 

Contact us